Luciferase Reporter Cell Line - HuCCT1

HuCCT1 is a human cholangiocarcinoma cell line derived from biliary epithelial cells. Cholangiocarcinoma, also known as bile duct cancer, is a rare but highly aggressive cancer with limited treatment options. The HuCCT1 cell line was established from a primary intrahepatic cholangiocarcinoma tumor and serves as a valuable model for studying the molecular mechanisms, signaling pathways, and treatment responses of this type of cancer. These cells exhibit epithelial cell morphology and retain characteristics of cholangiocytes, including the expression of cytokeratin markers. Researchers utilize HuCCT1 cells to investigate tumor progression, metastasis, and drug resistance mechanisms, thereby providing insights into potential targeted therapies for cholangiocarcinoma patients.

The luciferase reporter cell line - HuCCT1 is constructed by stably integrating a luciferase gene, controlled by a specific promoter or response element, into the HuCCT1 cell line. This modification allows researchers to quantitatively measure gene expression, promoter activity, or signaling pathway activation in real-time using bioluminescence imaging. Applications include high-throughput drug screening to identify compounds that modulate signaling pathways such as NF-κB, Wnt, or Hippo, which are aberrantly regulated in cholangiocarcinoma. This cell line is also used to study transcriptional regulation, monitor tumor growth in xenograft models, and evaluate the efficacy of immunotherapies or combination therapies. By providing a sensitive and non-invasive readout, this reporter system accelerates the discovery of biomarkers and the preclinical validation of novel targeted therapies for cholangiocarcinoma.